When is targeted therapy recommended for Waldenstrom macroglobulinaemia?

Waldenstrom macroglobulinaemia is a blood cancer involving abnormal lymphoplasmacytic cells and an antibody called immunoglobulin M. Treatment is often considered when the disease causes problems such as troublesome fatigue, anaemia, bleeding, enlarged lymph nodes, nerve symptoms, kidney effects, or thickened blood symptoms. A person without treatment-related problems may instead have regular monitoring.

Targeted medicines interfere with signals that help the abnormal cells survive. Your haematology team considers blood counts, immunoglobulin levels, symptoms, organ function, genetic or molecular findings when relevant, other illnesses, and medicines you already take. The plan may use targeted therapy alone or alongside another treatment.

Keep a record of headaches, blurred vision, dizziness, numbness, breathlessness, unusual bruising, infections, and changes in energy. Ask whether your blood needs urgent treatment before a longer-term medicine starts. Review vaccines, infection risks, dental work, and medicines that affect bleeding or heart rhythm.

Ask how often blood tests are needed, how tablets or infusions are given, what side effects should be reported, and what happens if the response is incomplete. See [Targeted Therapy](/treatments/systemic-therapy/targeted-therapy/) for a general explanation.

Seek urgent medical help for sudden confusion, severe headache, new vision changes, chest pain, major breathlessness, fainting, uncontrolled bleeding, or one-sided weakness. Contact your care team promptly for fever, worsening numbness, black stools, or rapidly increasing fatigue, especially during treatment.

What problem makes treatment necessary now? Which blood or molecular findings affect the choice? Would a targeted medicine be combined with another treatment? How will you monitor blood counts, infections, bleeding, and response?